Eversense: A Continuous Glucose Monitor That Lasts Three Months
February 18, 2019
Say Goodbye to Weekly Sensor Self-Insertions with Eversense
From diet and medication, to constant vigilance of blood glucose levels, day-to-day management of diabetes is a full-time job. With advancements in research, certain innovations help patients better manage the disease to live fuller, healthier lives.
Join us as The Balancing Act travels to Atlanta, Georgia to learn more about the disease from Dr. Bruce Bode, a leading endocrinologist. We also sit down with Laura Kronen, who shares her experience with managing diabetes.
Then, we receive an inside look at a cutting-edge device that leverages digital technology to improve the lives of those affected by diabetes. Engineered for long-lasting accuracy and ease of use, the Eversense Long-Term Continuous Glucose Monitoring (CGM) System offers advantages over traditional CGM.
The Eversense is changing the game for people living with diabetes. This particular device is the first and only long-term CGM that lasts up to 90 days and is placed in your arm. That means no weekly sensor self-insertions.
In addition, it quickly detects glucose highs and lows. In clinical studies, the Eversense system detected 95% of hypoglycemic episodes (70 mg/dL) and 99% of hyperglycemic episodes (180 mg/dL) within 15 minutes.
It also features alerts you can see, feel, and hear. The system can be configured to provide three types of alerts: visual, auditory, and on-body vibe alerts, which can provide you with an additional safety advantage, even during sleep.
The best part? It’s discreet and flexible. The smart transmitter, with its low profile and flexibility to remove and reattach without wasting a sensor, enables a new level of discretion.
Stay tuned as Laura receives the Eversense for the first time. You don’t want to miss this!
Bringing the best tips from the experts in Atlanta in business, beauty, wealth management, child healthcare, car shopping, and more. Each year, Atlanta’s Women’s Entrepreneurship Initiative selects 15 local female entrepreneurs for a 15-month business training program. We meet women who have grown their companies, created jobs, and broke through the glass ceiling. With some […]
iMCD is the deadliest subtype of Castleman disease. Approximately one third of patients die within five years of diagnosis, and another third die within 10 years if not treated.
There are no effective treatment options for people with unresectable or metastatic chondrosarcoma despite many attempts by multiple pharmaceutical companies over the past few decades.